Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells

For metastatic bladder cancer patients, systemic cisplatin (CDDP)-based combination chemotherapy is the first-line choice of treatment. Although up to 70% of advanced bladder cancer patients initially show good tumor response to this form of combination chemotherapy, over 90% of good responders rela...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Cancer
Egile Nagusiak: Tatokoro, Manabu, Koga, Fumitaka, Yoshida, Soichiro, Kawakami, Satoru, Fujii, Yasuhisa, Neckers, Len, Kihara, Kazunori
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447157/
https://ncbi.nlm.nih.gov/pubmed/21964864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.26475
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak